Key result
One Russian ISCHEMIA site shows >80% of stable CHD patients receive beta-blockers and ACEi/ARBs.
RCT
randomized
Yes
Baseline characteristics in this Level 5 cohort may differ from older trials; leaves open whether current revascularization guidelines apply to contemporary stable CHD populations.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bershteyn et al. (2017) conducted an RCT in stable coronary heart disease. Coronary revascularization was evaluated. Baseline analysis of patients with stable coronary heart disease at a single Russian site of the ISCHEMIA trial showed that >80% were treated with beta blockers and ACE inhibitors/ARBs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: